NuCana plc
NCNA
Rank in Stocks
#30988
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Share Price
$0.9326
Last synced: 2026-11-13
Market Cap
$3.90M
Change (1 day)
0.28%
Change (1 year)
-72.65%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade NuCana plc (NCNA)
Category
Healthcare
EPS for NuCana plc (NCNA)
EPS as of June 2026 TTM: $-4.00
According to NuCana plc's latest financial reports, its current EPS (TTM) is $-4.00. At the end of 2025 the company had an EPS of $-23.13, an increase over its 2024 EPS of $-2.05K.
EPS history for NuCana plc from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.00 | -82.72% |
| 2025 | $-23.13 | -98.87% |
| 2024 | $-2.05K | -50.63% |
| 2023 | $-4.16K | -8.96% |
| 2022 | $-4.57K | -36.92% |
| 2021 | $-7.24K | 1.99% |
| 2020 | $-7.10K | 26.73% |
| 2019 | $-5.60K | 52.42% |
| 2018 | $-3.68K | -42.70% |
| 2017 | $-6.42K | -482.45% |
| 2016 | $1.68K | -188.91% |
| 2015 | $-1.89K | 48,378,794.87% |
| 2014 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.99 | -75.23% |
US
|
|
| $15.66 | -491.84% |
US
|
|
| $-7.07 | 76.90% |
US
|
|
| $-5.29 | 32.37% |
AU
|
|
| $12.88 | -422.28% |
BE
|
Questions about NuCana plc's earnings per share (EPS)
What is NuCana plc's earnings per share (EPS)?
NuCana plc's earnings per share (EPS) over the last twelve months is $-4.00, as of Jun 2026.
What was NuCana plc's earnings per share (EPS) in 2025?
In 2025, NuCana plc's earnings per share (EPS) was $-23.13, compared with $-2.05K in 2024.
How has NuCana plc's earnings per share (EPS) changed since 2020?
From 2020 to 2025, NuCana plc's earnings per share (EPS) was highest in 2025 ($-23.13) and lowest in 2021 ($-7.24K).
How does NuCana plc's earnings per share (EPS) compare with similar companies?
NuCana plc's earnings per share (EPS) ($-4.00) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.